Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Emphysema

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    105 result(s) found for: Emphysema. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2015-004110-23 Sponsor Protocol Number: GTi1201-OLE Start Date*: 2016-03-29
    Sponsor Name:Grifols Therapeutics LLC
    Full Title: An Open-Label, Multicenter Study to Evaluate the Long-term Safety of Weekly Intravenous Alphal-Proteinase Inhibitor (Human), Modified Process 60 mg/kg in Subjects With Pulmonary Emphysema Due to Al...
    Medical condition: Pulmonary Emphysema due to Alpha-1-Antitrypsin Deficiency
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10014563 Emphysema pulmonary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) EE (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned) FI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-002525-23 Sponsor Protocol Number: NB19751C Start Date*: 2007-02-22
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A double-blind, placebo-controlled efficacy (as assessed by post-bronchodilator FEV1) and safety study of 5 mg RO3300074 once-daily for 2 years in subjects with smoking-related, moderate-to-severe...
    Medical condition: symptomatic smoking-related emphysema in ex-smokers
    Disease: Version SOC Term Classification Code Term Level
    8.1 10014561 Emphysema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) CZ (Completed) IS (Completed) LV (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-001870-38 Sponsor Protocol Number: GTi1201 Start Date*: 2014-01-09
    Sponsor Name:Grifols Therapeutics Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Two Dose Regimens (60 mg/kg and 120 mg/kg) of Weekly Intravenous Alphal-Proteinase Inhibitor (Human) in Sub...
    Medical condition: Pulmonary Emphysema due to Alpha-1-Antitrypsin Deficiency
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10014563 Emphysema pulmonary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) IE (Completed) EE (Completed) DK (Trial now transitioned) ES (Completed) FI (Trial now transitioned) PL (Trial now transitioned) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004869-18 Sponsor Protocol Number: 030547 Start Date*: 2008-07-03
    Sponsor Name:UHB NHS Foundation Trust
    Full Title: Evaluation of the relative severity of pulmonary neutrophilic inflammation and therapeutic modification with IV Prolastin by means of 18 FDG PET/CT scanning in subjects with alpha1-antitrypsin defi...
    Medical condition: The medical condition is emphysema and will be investigated in subjects with alpha 1-antitrypsin deficiency.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001811 Alpha-1 proteinase inhibitor deficiency LLT
    9.1 10014563 Emphysema pulmonary LLT
    9.1 10010952 COPD LLT
    9.1 10006458 Bronchitis chronic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-017872-26 Sponsor Protocol Number: 1147/09 Start Date*: 2010-02-22
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: Role and pharmacological modulation of lug inflammation in chronic obstructive pulmonary disease (COPD)
    Medical condition: chronic obstructive pulmonary disease
    Disease: Version SOC Term Classification Code Term Level
    12.1 10008842 Chronic bronchitis & emphysema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001853-15 Sponsor Protocol Number: NL61830 Start Date*: 2018-07-11
    Sponsor Name:Leiden University Medical Center
    Full Title: An explorative study for halting inflammation in patients with emphysema by intravenous administration of autologous bone marrow derived mesenchymal stromal cells.
    Medical condition: Pulmonary emphysema
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-001688-23 Sponsor Protocol Number: NA17598C Start Date*: 2004-10-27
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A multicentre, double-blind, placebo-controlled randomized trial of the efficacy, safety and tolerability of 12 months of once daily treatment with 1 mg of RO3300074 in patients with symptomatic em...
    Medical condition: symptomatic emphysema secondary to alpha-1-antitrypsin deficiency
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-003459-12 Sponsor Protocol Number: CE1226_4001 Start Date*: 2006-01-30
    Sponsor Name:CSL Behring GmbH
    Full Title: A Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase III/IV Study to compare the Efficacy and Safety of 60 mg/kg body weight of Zemaira® weekly i.v. administration with Placebo weekly ...
    Medical condition: Chronic augmentation and maintenance therapy in individuals with alpha1-proteinase inhibitor (A1-PI) deficiency and clinical evidence of emphysema.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004850 10001811 Alpha-1 proteinase inhibitor deficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) DE (Completed) FI (Completed) EE (Completed) SE (Completed) CZ (Completed) DK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2007-007129-38 Sponsor Protocol Number: CE1226_3001 Start Date*: 2008-03-14
    Sponsor Name:CSL Behring GmbH
    Full Title: An open-label, non-controlled, multicenter, multinational Study to evaluate the Efficacy and Safety of Zemaira® administration in Chronic Augmentation and Maintenance Therapy in Subjects with Emphy...
    Medical condition: Chronic augmentation and maintenance therapy in individuals with alpha1-proteinase inhibitor (A1-PI) deficiency and clinical evidence of emphysema.
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004850 10001811 Alpha-1 proteinase inhibitor deficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) CZ (Completed) DE (Completed) FI (Completed) SE (Completed) EE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-001749-42 Sponsor Protocol Number: 484/12 Start Date*: 2012-08-07
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: Effects of treatment and withdrawal with inhaled beclomethasone/formoterol on lung inflammation in COPD.
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10029977 Obstructive chronic bronchitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-005326-36 Sponsor Protocol Number: Kamada-AAT(inhaled)-007 Start Date*: 2009-11-02
    Sponsor Name:Kamada Limited
    Full Title: A Phase II/III, Double-Blind, Randomized, Placebo-Controlled, Multicenter, International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin...
    Medical condition: Alpha-1 Antitrypsin deficiency in patients with emphysema.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10010331 - Congenital, familial and genetic disorders 10001806 Alpha-1 anti-trypsin deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) SE (Completed) DK (Completed) DE (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2009-012231-15 Sponsor Protocol Number: ML22608 Start Date*: 2009-11-10
    Sponsor Name:Roche Pharma AG
    Full Title: Pharmacokinetics of Mycophenolate Mofetil in de novo lung allograft recipients
    Medical condition: Prevention of acute allograft rejections in de novo lung allograft recipients
    Disease: Version SOC Term Classification Code Term Level
    12.0 10051604 Lung transplant rejection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002563-23 Sponsor Protocol Number: CD-RI-MEDI8968-1103 Start Date*: 2012-03-15
    Sponsor Name:MedImmune Limited
    Full Title: A Phase 2 Double-blind, Placebo-controlled Study to Evaluate the Efficacy of MEDI8968 in Chronic Obstructive Pulmonary Disease
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) LV (Completed) CZ (Completed) LT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2018-002173-22 Sponsor Protocol Number: 201800406 Start Date*: 2018-12-04
    Sponsor Name:University Medical Center Groningen
    Full Title: Anti-inflammatory effects of tiotropium in patients with stable COPD
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000822-24 Sponsor Protocol Number: VP-C21-005 Start Date*: 2020-07-06
    Sponsor Name:Vicore Pharma AB
    Full Title: A Phase 2, Multi-Centre, Open-Label, Single-Arm Trial Investigating the Safety, Efficacy and Pharmacokinetics of C21 in Subjects with Idiopathic Pulmonary Fibrosis
    Medical condition: Idiopathic Pulmonary Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2008-000896-30 Sponsor Protocol Number: Uni-Koeln-439 Start Date*: 2009-02-09
    Sponsor Name:University of Cologne
    Full Title: Surfactant application during spontaneous breathing with CPAP or during mechanical ventilation in the therapy of IRDS in premature infants <27 weeks
    Medical condition: Idiopathic Respiratory Distress Syndrome (IRDS) in preterm infants
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10021735 Infant respiratory distress syndrome LLT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-000053-21 Sponsor Protocol Number: FLUI-2014-134 Start Date*: 2015-05-05
    Sponsor Name:FLUIDDA nv
    Full Title: Placebo controlled study to assess the effect of Roflumilast in hyperinflated COPD patients in addition to LABA/LAMA therapy using Functional Respiratory Imaging.
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-000982-30 Sponsor Protocol Number: 4993/15 Start Date*: 2016-08-08
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: Personalized pharmacological treatment of chronic obstructive pulmonary disease based on phenotyping: interventional study
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004855 10070975 Chronic obstructive bronchopneumopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003931-12 Sponsor Protocol Number: BXU513667 Start Date*: 2017-12-13
    Sponsor Name:Baxter Healthcare Corporation
    Full Title: A Randomized Controlled Non-inferiority Study to Evaluate the Efficacy and Safety of Hemopatch Compared to TachoSil in Preventing or Reducing Postoperative Air Leaks After Pulmonary Resection.
    Medical condition: Postoperative air leakage.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10067826 Pulmonary air leakage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-002362-37 Sponsor Protocol Number: GlaxoSmithKline, B2C101762 Start Date*: 2004-12-22
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A multicentre, randomised, double-blind, placebo-controlled, dose ascending, four way crossover study to examine efficacy (FEV1),safety, tolerability, pharmacodynamics and pharmacokinetics of sing...
    Medical condition: GW642444 is a new potent and selective inhaled beta-2-receptor agonist, which is being developed for once daily treatment of asthma and COPD.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 01:12:14 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA